ArticleJB & JS open access
Heterotopic Ossification in Cementless Trochanteric Sparing Short Stem Total Hip Arthroplasty: Clinical Impact and Implant-Level Risk Assessment.
Article in JB & JS open access. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Heterotopic ossification (HO) is a common complication of total hip arthroplasty (THA), which can adversely affect patient satisfaction. Although the direct anterior approach (DAA) has been associated with lower rates of HO, the exact clinical impact of even low-grade ossification following DAA THA remains underreported. We aimed to assess the clinical impact of HO in DAA THA and identify demographics and implant-related risk factors. Methods: A retrospective single-center cohort study of 348 hips treated via DAA THA with a cementless short stem between January 2011 and December 2021 was performed. HO was graded at ≥12 months using the Brooker classification on standardized anteroposterior radiographs. The Harris Hip Score (HHS), the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and the Visual Analogue Scale (VAS) were assessed at a mean of 4.3 years of follow-up. Comparative analyses and multivariable logistic regression were performed to identify independent predictors of HO. Results: HO occurred in 18.1% of hips: Brooker grade I in 12.4%, II in 3.0%, and III in 3.0%; no grade IV lesions developed. At final follow-up, patients without HO had significantly better outcomes compared with those with HO (all p < 0.001). When stratified by severity, even low-grade HO (Brooker I-II) was associated with significantly worse WOMAC (p = 0.023) and HHS (p < 0.001) compared with the non-HO group. Although VAS pain was higher in the low-grade group, the difference did not reach statistical significance (p = 0.084). On multivariable analysis, independent implant-related risk factors included use of the Continuum acetabular cup (odds ratio [OR] 2.10; p = 0.014), each additional millimeter of cup diameter (OR 1.16; p = 0.003), and longer femoral neck length (OR 2.06; p = 0.006). Conclusions: HO was observed in nearly one-fifth of hips, and even low-grade ossification was associated with significantly worse mid-term functional outcomes. Cup design, size, and neck length were identified as significant, modifiable predictors of HO risk. Careful implant selection may help reduce the incidence of HO and enhance postoperative function. Level of Evidence: Therapeutic Level II. See Instructions for Authors for a complete description of levels of evidence.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.